Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 212

1.

Can IL-23 be a good target for ulcerative colitis?

Allocca M, Furfaro F, Fiorino G, Gilardi D, D'Alessio S, Danese S.

Best Pract Res Clin Gastroenterol. 2018 Feb - Apr;32-33:95-102. doi: 10.1016/j.bpg.2018.05.016. Epub 2018 May 23. Review.

PMID:
30060945
2.

CME Part I Psoriasis: Which Therapy for Which Patient Psoriasis comorbidities and preferred systemic agents.

Kaushik SB, Lebwohl MG.

J Am Acad Dermatol. 2018 Jul 11. pii: S0190-9622(18)32215-1. doi: 10.1016/j.jaad.2018.06.057. [Epub ahead of print] Review.

PMID:
30017705
3.

p19-Targeting ILP Protein Blockers of IL-23/Th-17 Pro-Inflammatory Axis Displayed on Engineered Bacteria of Food Origin.

Škrlec K, Zadravec P, Hlavničková M, Kuchař M, Vaňková L, Petroková H, Křížová L, Černý J, Berlec A, Malý P.

Int J Mol Sci. 2018 Jul 1;19(7). pii: E1933. doi: 10.3390/ijms19071933.

4.

Genome-wide association studies in Crohn's disease: Past, present and future.

Verstockt B, Smith KG, Lee JC.

Clin Transl Immunology. 2018 Jan 31;7(1):e1001. doi: 10.1002/cti2.1001. eCollection 2018. Review.

5.

[Emerging Therapies: What Are Promising in the Near Future?]

Seo GS, Lee SH.

Korean J Gastroenterol. 2018 Feb 25;71(2):81-88. doi: 10.4166/kjg.2018.71.2.81. Review. Korean.

6.

Intestinal IFN-γ-producing type 1 regulatory T cells coexpress CCR5 and programmed cell death protein 1 and downregulate IL-10 in the inflamed guts of patients with inflammatory bowel disease.

Alfen JS, Larghi P, Facciotti F, Gagliani N, Bosotti R, Paroni M, Maglie S, Gruarin P, Vasco CM, Ranzani V, Frusteri C, Iseppon A, Moro M, Crosti MC, Gatti S, Pagani M, Caprioli F, Abrignani S, Flavell RA, Geginat J.

J Allergy Clin Immunol. 2018 Jan 31. pii: S0091-6749(18)30078-2. doi: 10.1016/j.jaci.2017.12.984. [Epub ahead of print]

7.

Clinical Significance of Bmi1 Expression in Inflammatory Bowel Disease.

Yamada M, Sakurai T, Komeda Y, Nagai T, Kamata K, Minaga K, Yamao K, Takenaka M, Hagiwara S, Matsui S, Watanabe T, Nishida N, Kashida H, Kudo M.

Oncology. 2017;93 Suppl 1:20-26. doi: 10.1159/000481225. Epub 2017 Dec 20.

8.

Ustekinumab to treat Crohn's disease.

Gisbert JP, Chaparro M.

Gastroenterol Hepatol. 2017 Dec;40(10):688-698. doi: 10.1016/j.gastrohep.2017.08.006. Epub 2017 Oct 16. Review. English, Spanish.

PMID:
29042094
9.

The Expanding Therapeutic Armamentarium for Inflammatory Bowel Disease: How to Choose the Right Drug[s] for Our Patients?

Hindryckx P, Vande Casteele N, Novak G, Khanna R, D'Haens G, Sandborn WJ, Danese S, Jairath V, Feagan BG.

J Crohns Colitis. 2018 Jan 5;12(1):105-119. doi: 10.1093/ecco-jcc/jjx117. Review.

PMID:
28961959
10.

A novel function of CXCL10 in mediating monocyte production of proinflammatory cytokines.

Zhao Q, Kim T, Pang J, Sun W, Yang X, Wang J, Song Y, Zhang H, Sun H, Rangan V, Deshpande S, Tang H, Cvijic ME, Westhouse R, Olah T, Xie J, Struthers M, Salter-Cid L.

J Leukoc Biol. 2017 Nov;102(5):1271-1280. doi: 10.1189/jlb.5A0717-302. Epub 2017 Sep 12.

PMID:
28899907
11.

Ustekinumab and Anti-Interleukin-23 Agents in Crohn's Disease.

Deepak P, Sandborn WJ.

Gastroenterol Clin North Am. 2017 Sep;46(3):603-626. doi: 10.1016/j.gtc.2017.05.013. Review.

PMID:
28838418
12.

Targeting Specific Immunologic Pathways in Crohn's Disease.

Ramos GP, Faubion WA, Papadakis KA.

Gastroenterol Clin North Am. 2017 Sep;46(3):577-588. doi: 10.1016/j.gtc.2017.05.009. Epub 2017 Jul 19. Review.

PMID:
28838416
13.

Positioning Ustekinumab in Crohn's Disease: From Clinical Evidence to Clinical Practice.

Danese S, Bonovas S, Peyrin-Biroulet L.

J Crohns Colitis. 2017 Oct 1;11(10):1258-1266. doi: 10.1093/ecco-jcc/jjx079. Review.

PMID:
28575273
14.

Ustekinumab: A Review in Moderate to Severe Crohn's Disease.

Lamb YN, Duggan ST.

Drugs. 2017 Jul;77(10):1105-1114. doi: 10.1007/s40265-017-0765-6. Review.

PMID:
28528528
15.

Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study.

Feagan BG, Sandborn WJ, D'Haens G, Panés J, Kaser A, Ferrante M, Louis E, Franchimont D, Dewit O, Seidler U, Kim KJ, Neurath MF, Schreiber S, Scholl P, Pamulapati C, Lalovic B, Visvanathan S, Padula SJ, Herichova I, Soaita A, Hall DB, Böcher WO.

Lancet. 2017 Apr 29;389(10080):1699-1709. doi: 10.1016/S0140-6736(17)30570-6. Epub 2017 Apr 12.

16.

Targeting interleukin 23 for Crohn's disease: finding the right drug for the right patient.

Hanauer SB.

Lancet. 2017 Apr 29;389(10080):1671-1672. doi: 10.1016/S0140-6736(17)30977-7. Epub 2017 Apr 12. No abstract available.

PMID:
28411871
17.

Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn's Disease: A Phase 2a Study.

Sands BE, Chen J, Feagan BG, Penney M, Rees WA, Danese S, Higgins PDR, Newbold P, Faggioni R, Patra K, Li J, Klekotka P, Morehouse C, Pulkstenis E, Drappa J, van der Merwe R, Gasser RA Jr.

Gastroenterology. 2017 Jul;153(1):77-86.e6. doi: 10.1053/j.gastro.2017.03.049. Epub 2017 Apr 5.

18.

Inflammatory Bowel Disease: New Therapeutic Options in the Post Anti-TNFα Era.

Jiménez-Pérez M, Olmedo-Martín RV, Amo-Trillo VM, González-Gande R.

Curr Drug Metab. 2017;18(7):666-679. doi: 10.2174/1389200218666170406120203. Review.

PMID:
28382862
19.

Protease-activated Receptor 1 Plays a Proinflammatory Role in Colitis by Promoting Th17-related Immunity.

Saeed MA, Ng GZ, Däbritz J, Wagner J, Judd L, Han JX, Dhar P, Kirkwood CD, Sutton P.

Inflamm Bowel Dis. 2017 Apr;23(4):593-602. doi: 10.1097/MIB.0000000000001045.

PMID:
28296821
20.

Increased expression of IL12B mRNA transcribed from the risk haplotype for Crohn's disease is a risk factor for disease relapse in Japanese patients.

Kakuta Y, Kimura T, Negoro K, Kuroha M, Shiga H, Endo K, Kinouchi Y, Shimosegawa T.

J Gastroenterol. 2017 Dec;52(12):1230-1239. doi: 10.1007/s00535-017-1322-5. Epub 2017 Feb 22.

PMID:
28229296

Supplemental Content

Loading ...
Support Center